RxDoctor Payments Data

Marc Merbaum, MD

Internal Medicine · Saint Louis, MONPI 1245204338

Payments from drug & device makers

$823in general payments, 2019–2025

Across 46 payments — averaging $17.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$222
  • Astellas Pharma US Inc$92
  • Lilly USA, LLC$89
  • GSK$87
  • Pfizer$56
  • Sumitomo Pharma America, Inc.$39
  • plus $237 from 10 others

What the payments were for

  • Food & beverage$823100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$823 in reported general payments places this provider in the 70th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$106,707
Medicare patients
233
Services billed
3,306

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban218$197,653
OzempicSemaglutide63$100,434
JanuviaSitagliptin Phosphate72$90,958
TradjentaLinagliptin66$60,725
MounjaroTirzepatide37$52,219
XareltoRivaroxaban45$50,329
Trelegy ElliptaFluticasone/Umeclidin/Vilanter53$36,290
JardianceEmpagliflozin29$35,715
Breo ElliptaFluticasone/Vilanterol40$27,621
TrulicityDulaglutide18$27,346
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr25$22,967
Semglee (Yfgn) PenInsulin Glargine-Yfgn47$19,006
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$14,022
MyrbetriqMirabegron19$12,102
ArexvyRsvpref3 Antigen/As01e/Pf41$11,501

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$56$197,653218 claims
Novo NordiskOzempic$26$100,43463 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arexvy$87$98,379159 claims
Lilly USA, LLCMounjaro, Trulicity$89$79,56555 claims
Johnson & JohnsonXarelto$27$50,32945 claims
AstraZenecaFarxiga, Symbicort$36$14,05926 claims
Astellas Pharma US IncMyrbetriq$92$12,10219 claims
AbbVieSynthroid$222$2,55027 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →